# Study of Safety and Tolerability of DCR HBVS

> **NCT03772249** · PHASE1 · COMPLETED · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 82 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** DCR-HBVS
- **DRUG:** Placebo for DCR-HBVS

## Key facts

- **NCT ID:** NCT03772249
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-28
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772249, "Study of Safety and Tolerability of DCR HBVS". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03772249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*